Irinotecan Versus Only Best Supportive Care for Gastric Cancer

Status Completed

Clinical Trial Summary

The median survival at progression after first-line chemotherapy for metastatic gastric cancer is about 2.5 months. There are no data which a possible benefit of second line therapy. for this reason a trial which investigates a possible benefit or chemotherapy compared to best supportive care as second line treatment is urgently necessary.

Irinotecan shows response rates of 20% in the first line therapy with high rates od disease stabilization. There are few trials investigating irinotecan in the second line setting. Response rates of 20% are reported in tis setting. Irinotecan is supplied without costs from the company Pfizer.

Clinical Trial Description

Metastatic gastric cancer, progressive disease after one palliative chemotherapy

Arm A:

Irinotecan 250/350 mg/m2 q3w

1. Cycle:250mg/m2/ 30min

2. Cycle:If no toxicity>2° CTC, nor Leuko-thrombopenia>3° occured, dose is increased to 350mg/m2 Arm B. Best supportive care ;

Study Design

Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT00144378
Study type	Interventional
Source	Charite University, Berlin, Germany
Contact
Status	Completed
Phase	Phase 3
Start date	October 2002

View Details

See also
Status	Clinical Trial	Phase
Withdrawn	`NCT06057636` - Hypnosis for Pain in Black Women With Advanced Breast Cancer: A Feasibility Study	N/A
Terminated	`NCT03166631` - A Trial to Find the Safe Dose for BI 891065 Alone and in Combination With BI 754091 in Patients With Incurable Tumours or Tumours That Have Spread	Phase 1
Terminated	`NCT01441115` - ECI301 and Radiation for Advanced or Metastatic Cancer	Phase 1
Active, not recruiting	`NCT03775980` - CIRSE Emprint Microwave Ablation Registry
Completed	`NCT01114958` - Pilot Study of Intra-Arterial Cisplatin With IV Thiosulfate in Patients With Lung Cancer or Lung Metastases	Phase 1
Terminated	`NCT03986593` - Cryoablation of Bone Metastases From Endocrine Tumors	N/A
Active, not recruiting	`NCT04458259` - Study of PF-07265807 in Participants With Metastatic Solid Tumors.	Phase 1
Completed	`NCT01218542` - Whole Brain Radiation Therapy With Boost to Metastatic Tumor Volume Using RapidArc	N/A
Not yet recruiting	`NCT03175146` - A Study to See Whether Stereotactic Body RadioTherapy (SBRT) Can Shrink Tumours Within the Liver Safely	N/A
Active, not recruiting	`NCT02395224` - A Longitudinal Study of Colorectal Cancer Patients With Metastatic Disease in Middle-Norway
Completed	`NCT02374411` - Knowledge, Attitudes, and Practice of Surgeons Toward Nutrition Support in HIPEC Patients	N/A
Recruiting	`NCT01960829` - Everolimus in Selected Patients With Metastatic Melanoma: Efficacy and Safety Study	Phase 2
Terminated	`NCT01846429` - Oral Bicarbonate as Adjuvant for Pain Reduction in Patients With Tumor Related Pain	Phase 1
Completed	`NCT01933789` - Improving Communication About Serious Illness	N/A
Recruiting	`NCT01564810` - Cetuximab in Combination With Chemotherapy for the Treatment of Metastatic Colorectal Cancer	Phase 4
Completed	`NCT00375245` - Rapamycin With Grapefruit Juice for Advanced Malignancies	Phase 1
Completed	`NCT00207116` - An Exploratory Pharmacogenomic Study of Monotherapy Erbitux in Subjects With Metastatic Non Small Cell Lung Carcinoma	Phase 1
Completed	`NCT00232726` - Clinical Study of Previously Untreated Patients With Malignant Melanoma	Phase 2
Completed	`NCT00207103` - MAD in Cancer Patients: Safety of BMS-582664 in Patients With Advanced or Metastatic Solid Tumors	Phase 1
Completed	`NCT00172003` - Effect of Zoledronic Acid in Patients With Renal Cell Cancer and Bone Metastasis	Phase 4